CryoLife, Inc. Cost of Revenue

Cost of Revenue of CRY for past 10 years: annual, quarterly and twelve month trailing (TTM) including Cost of Revenue growth rates and interactive chart. Cost of revenue refers to the direct costs attributable to the production of the goods or supply of services by an entity. It is also commonly known as the “cost of goods sold (COGS)”. Cost of sales measures the cost of goods produced or services provided in a period by an entity. It includes the cost of the direct materials used in producing the goods, direct labor costs used to produce the good, along with any other direct costs associated with the production of goods. In case of services cost of sales includes the labor cost or salaries of the employees and other directly attributable costs. Cost of sales does not include indirect expenses such as distribution costs and marketing costs. It appears on the income statement and is deducted from the sales revenue for the calculation of gross profit (or gross margin).

Highlights and Quick Summary

  • Cost of Revenue for the quarter ending March 30, 2021 was $27.7 Million (a 0.09% increase compared to previous quarter)
  • Year-over-year quarterly Cost of Revenue increased by 31.47%
  • Annual Cost of Revenue for 2020 was $99.2 Million (a -4.66% decrease from previous year)
  • Annual Cost of Revenue for 2019 was $104 Million (a 3.39% increase from previous year)
  • Annual Cost of Revenue for 2018 was $101 Million (a 52.16% increase from previous year)
  • Twelve month Cost of Revenue ending March 30, 2021 was $102 Million (a 2.22% increase compared to previous quarter)
  • Twelve month trailing Cost of Revenue increased by 10.41% year-over-year
Trailing Cost of Revenue for the last four month:
30 Mar '21 30 Dec '20 29 Sep '20 29 Jun '20
$102 Million $99.7 Million $95.2 Million $92.3 Million
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Cost of Revenue of CryoLife, Inc.

Most recent Cost of Revenueof CRY including historical data for past 10 years.

Interactive Chart of Cost of Revenue of CryoLife, Inc.

CryoLife, Inc. Cost of Revenue for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $27.66
2020 $27.64 $25.56 $21.04 $25.45 $99.21
2019 $23.15 $22.66 $24.17 $23.23 $104.06
2018 $21.85 $22.65 $22.65 $22.72 $100.65
2017 $16.46 $14.14 $14.91 $15.55 $66.15
2016 $13.83 $15.47 $16.78 $15.4 $65.91
2015 $13.32 $13.72 $13.97 $14.16 $55.18
2014 $14.52 $13.27 $12.31 $13.26 $53.35
2013 $13.18 $12.9 $12.04 $12.26 $50.38
2012 $11.76 $12.12 $11.82 $11.01 $46.7
2011 $11.02 $10.74 $10.33 $11.69 $43.78
2010 $11.64 $13.22 $11.49 $48.28

Business Profile of CryoLife, Inc.

Sector: Healthcare
Industry: Medical Devices
CryoLife, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. It offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X prosthetic aortic and mitral heart valve, and On-X ascending aortic prosthesis; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita OPEN PLUS and E-vita OPEN NEO, a hybrid stent graft system. The company also provides E-xtra DESIGN ENGINEERING products for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, it offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; and cardiac laser therapy products, such as SolarGen 2100s Console and SoloGrip III disposable handpieces. Further, the company sells CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as offers pyrolytic carbon coating services to other medical device manufacturers. The company serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. CryoLife, Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.